Medicenna Therapeutics Corp has seen a slight decline this week amid several notable company updates.
This week, Medicenna Therapeutics Corp (MDNA.TO) experienced a price movement of -2.53%, closing at C$0.41. Despite the recent downturn, the company has been active in its corporate governance and financial reporting, which may influence investor sentiment moving forward.
Advertisement
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeMarket cap
$37.84M
52W high
$1.97
52W low
$0.34
1W change
-2.53%
Beta
2.10
Analyst Price Targets
Based on analyst covering MDNA · as of Sep 17, 2026
Wall Street analysts forecast MDNA stock price to rise 731.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+731.2% Upside
Current Price
C$0.39
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
50.8%
Annualized
90-Day Vol
51.4%
Annualized
Trend (90d)
+37.5%
Annualized drift
90d Mean
C$0.47
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.43 | C$0.36 – C$0.51 |
| 60 trading days | C$0.45 | C$0.35 – C$0.57 |
| 90 trading days | C$0.47 | C$0.35 – C$0.64 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider the implications of Medicenna's recent shareholder meeting and upcoming presentations, while also keeping an eye on the stock's technical indicators and overall market conditions.
Medicenna's stock is currently trading at C$0.41, down 61.50% year-to-date.
The stock has a 52-week range of C$0.34 to C$1.97, indicating it is currently near the lower end of its range.
Bull case
Analysts have a positive outlook for Medicenna, with an average target price of C$3.20. This suggests there’s significant upside potential. The company’s recent public offerings have raised capital that can support its lead programs, potentially driving future growth.
Bear case
Despite the growth potential, Medicenna's stock has significantly underperformed this year, down 61.50%. Technical indicators also show weakness, as the stock is trading well below its 200-day moving average.
Price Action Overview
Advertisement
As of the latest trading session, Medicenna Therapeutics Corp's stock closed at C$0.41, reflecting a 1D change of +0.00%. Over the past week, the stock has seen a decline of 2.53%, while its monthly performance shows a more significant drop of 18.09%. Year-to-date, the stock has plummeted by 61.50%, highlighting a challenging market environment for the company.
Recent Company News
Medicenna has been in the headlines recently for several developments. Notably, the company announced the results of its Annual General and Special Meeting, where all director nominees were elected with over 97% shareholder approval. Additionally, Medicenna is set to present at the H.C. Wainwright 28th Annual Global Investment Conference, which could provide further visibility for the company. The company also released its Q1 fiscal 2027 financial results and announced upcoming oral presentations at conferences, indicating ongoing efforts to engage with investors and stakeholders.
Technical Picture
From a technical perspective, Medicenna's stock is currently trading at its 50-day moving average of C$0.41, showing a slight decline of 0.3% compared to the price. However, the stock is significantly below its 200-day moving average of C$0.61, reflecting a 32.3% gap. The stock's 52-week range of C$0.34 to C$1.97 indicates that it is trading near the lower end of this range. With a beta of 1.96, the stock is more volatile than the market, which could present both risks and opportunities for investors.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
